Senseonics Holdings, Inc. — Third Quarter 2026 Earnings Summary

Senseonics Holdings, Inc. reported third-quarter 2026 revenue of $19.6 million, representing a 140% increase year-over-year, driven by a 160% rise in U.S. sales to $16.8 million. The company achieved a gross margin of approximately 62% and raised its full-year 2026 revenue guidance to a range of $68 million to $70 million. Net loss for the quarter was $32.7 million, or $0.50 per share, while the company announced a strategic partnership with Beta Bionics to integrate Eversense 365 with the iLet Bionic Pancreas system. Additionally, Senseonics initiated a first-in-human study for its investigational Freedom CGM system and expanded its EON Care network to over 100 inserters.